Recent News

• 05.15.2025 - Tivic Reports First Quarter 2025 Financial Results and Provides Updates on Business Transformation
• 05.14.2025 - Tivic Health Enters GMP Manufacturing Validation Agreement with Scorpius BioManufacturing in Preparation for FDA Submission
• 05.13.2025 - Tivic Expands VNS Intellectual Property Portfolio
• 05.09.2025 - Tivic Health to Report First Quarter 2025 Financial Results on May 15th Via Conference Call and Webcast
• 04.15.2025 - Tivic Health Extends its Worldwide License of TLR5 Agonist Entolimod to Include the Treatment of Neutropenia
• 04.10.2025 - Tivic Health Systems, Inc. Regains Compliance with NASDAQ Minimum Bid Price Listing Rule

Recent Filings

• 05.15.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 05.15.2025 - EX-99.1 EX-99.1
• 05.15.2025 - 8-K Current report
• 05.14.2025 - 8-K Current report
• 05.14.2025 - EX-99.1 EX-99.1
• 05.13.2025 - 424B3 Prospectus [Rule 424(b)(3)]
• 05.13.2025 - EFFECT Notice of Effectiveness
• 05.09.2025 - S-1 General form for registration of securities under the Securities Act of 1933
• 05.02.2025 - DRS Draft Registration Statement
• 05.02.2025 - 8-K Current report